214 related articles for article (PubMed ID: 34035391)
1. Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis.
Vizeli P; Straumann I; Holze F; Schmid Y; Dolder PC; Liechti ME
Sci Rep; 2021 May; 11(1):10851. PubMed ID: 34035391
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.
Dolder PC; Schmid Y; Steuer AE; Kraemer T; Rentsch KM; Hammann F; Liechti ME
Clin Pharmacokinet; 2017 Oct; 56(10):1219-1230. PubMed ID: 28197931
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects.
Holze F; Duthaler U; Vizeli P; Müller F; Borgwardt S; Liechti ME
Br J Clin Pharmacol; 2019 Jul; 85(7):1474-1483. PubMed ID: 30883864
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants.
Holze F; Liechti ME; Hutten NRPW; Mason NL; Dolder PC; Theunissen EL; Duthaler U; Feilding A; Ramaekers JG; Kuypers KPC
Clin Pharmacol Ther; 2021 Mar; 109(3):658-666. PubMed ID: 32975835
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans.
Dolder PC; Schmid Y; Haschke M; Rentsch KM; Liechti ME
Int J Neuropsychopharmacol; 2015 Jun; 19(1):. PubMed ID: 26108222
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers.
Family N; Maillet EL; Williams LTJ; Krediet E; Carhart-Harris RL; Williams TM; Nichols CD; Goble DJ; Raz S
Psychopharmacology (Berl); 2020 Mar; 237(3):841-853. PubMed ID: 31853557
[TBL] [Abstract][Full Text] [Related]
7. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects.
Holze F; Vizeli P; Müller F; Ley L; Duerig R; Varghese N; Eckert A; Borgwardt S; Liechti ME
Neuropsychopharmacology; 2020 Feb; 45(3):462-471. PubMed ID: 31733631
[TBL] [Abstract][Full Text] [Related]
8. Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants.
Straumann I; Ley L; Holze F; Becker AM; Klaiber A; Wey K; Duthaler U; Varghese N; Eckert A; Liechti ME
Neuropsychopharmacology; 2023 Dec; 48(13):1840-1848. PubMed ID: 37258715
[TBL] [Abstract][Full Text] [Related]
9. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects.
Schmid Y; Enzler F; Gasser P; Grouzmann E; Preller KH; Vollenweider FX; Brenneisen R; Müller F; Borgwardt S; Liechti ME
Biol Psychiatry; 2015 Oct; 78(8):544-53. PubMed ID: 25575620
[TBL] [Abstract][Full Text] [Related]
10. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.
Holze F; Ley L; Müller F; Becker AM; Straumann I; Vizeli P; Kuehne SS; Roder MA; Duthaler U; Kolaczynska KE; Varghese N; Eckert A; Liechti ME
Neuropsychopharmacology; 2022 May; 47(6):1180-1187. PubMed ID: 35217796
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals.
Schmid Y; Vizeli P; Hysek CM; Prestin K; Meyer Zu Schwabedissen HE; Liechti ME
Pharmacogenet Genomics; 2016 Aug; 26(8):397-401. PubMed ID: 27253829
[TBL] [Abstract][Full Text] [Related]
12. A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers.
Ramaekers JG; Hutten N; Mason NL; Dolder P; Theunissen EL; Holze F; Liechti ME; Feilding A; Kuypers KP
J Psychopharmacol; 2021 Apr; 35(4):398-405. PubMed ID: 32842825
[TBL] [Abstract][Full Text] [Related]
13. Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects.
Strajhar P; Schmid Y; Liakoni E; Dolder PC; Rentsch KM; Kratschmar DV; Odermatt A; Liechti ME
J Neuroendocrinol; 2016 Mar; 28(3):12374. PubMed ID: 26849997
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use.
Luethi D; Hoener MC; Krähenbühl S; Liechti ME; Duthaler U
Biochem Pharmacol; 2019 Jun; 164():129-138. PubMed ID: 30981875
[TBL] [Abstract][Full Text] [Related]
15. Alterations of consciousness and mystical-type experiences after acute LSD in humans.
Liechti ME; Dolder PC; Schmid Y
Psychopharmacology (Berl); 2017 May; 234(9-10):1499-1510. PubMed ID: 27714429
[TBL] [Abstract][Full Text] [Related]
16. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers.
Bershad AK; Schepers ST; Bremmer MP; Lee R; de Wit H
Biol Psychiatry; 2019 Nov; 86(10):792-800. PubMed ID: 31331617
[TBL] [Abstract][Full Text] [Related]
17. Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study.
Hutten NRPW; Mason NL; Dolder PC; Theunissen EL; Holze F; Liechti ME; Feilding A; Ramaekers JG; Kuypers KPC
Eur Neuropsychopharmacol; 2020 Dec; 41():81-91. PubMed ID: 33082016
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide administration in healthy participants.
Holze F; Erne L; Duthaler U; Liechti ME
Br J Clin Pharmacol; 2024 Jan; 90(1):200-208. PubMed ID: 37596682
[TBL] [Abstract][Full Text] [Related]
19. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.
Holze F; Vizeli P; Ley L; Müller F; Dolder P; Stocker M; Duthaler U; Varghese N; Eckert A; Borgwardt S; Liechti ME
Neuropsychopharmacology; 2021 Feb; 46(3):537-544. PubMed ID: 33059356
[TBL] [Abstract][Full Text] [Related]
20. Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.
Ley L; Holze F; Arikci D; Becker AM; Straumann I; Klaiber A; Coviello F; Dierbach S; Thomann J; Duthaler U; Luethi D; Varghese N; Eckert A; Liechti ME
Neuropsychopharmacology; 2023 Oct; 48(11):1659-1667. PubMed ID: 37231080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
